To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
If we know the complete sequence of the human genome and understand how it works, and how tumours are formed, then we can begin to understand how to deal with tumours better.
Both of Fred Sanger’s parents died of cancer at relatively young ages, his father, Frederick, aged 60 in 1937 from an operation to remove a stomach cancer. His mother, Cicely, aged 58, died a year later from cancer of the colon. Fred Sanger was a young man of 20 then – still studying at Cambridge for his first degree. At that young age, he could not have imagined that later in his life it would be his research that would make the dream of sequencing the human genome a reality. In 1938 it would have been a leap of faith to predict that by the beginning of the twenty-first century, the entire human genome would have been sequenced.
Fred rarely allowed himself the luxury of predicting future results of research. ‘I don’t want to look into the future very much. I’m a scientist not an astrologer! I don’t like to predict things you can’t be too sure about.’ He believed in evidence, not in theories of what might be possible and how long it might take to solve a problem. But we know that Fred hoped that his research might lead to medical advances even though he rarely spoke about this in public. In 1992, in an interview with a journalist, he said: ‘If we know the complete sequence of the human genome and understand how it works, and how tumours are formed, then we can begin to understand how to deal with tumours better.’ The knowledge that cancer had caused the early death of both his parents may have been in the back of Fred’s mind when he made this remark.
Fred Sanger started his research in arguably the best-known biochemistry department in Britain in 1940 under the leadership of Frederick Gowland Hopkins. Hopkins, affectionately known as ‘Hoppy’, held the first Chair of Biochemistry in Cambridge from 1914 and had modernised biochemistry in the UK. Biochemistry had lagged behind advances in this subject in Europe, and particularly in Germany, in the previous century. The subject had evolved from physiological chemistry and was originally a branch of physiology with a chemical bias. But Hopkins, as the first Professor of Biochemistry in Cambridge – although not the first in the UK which was in Liverpool University in 1902 – established a vibrant British school of biochemistry even though he had an unconventional training as an analytical chemist and medic and had never formally studied biochemistry himself. ‘In Hopkins two things were significantly combined: the training and tastes of an organic chemist, and the imagination of a biologist and physician.’ A careful and committed experimentalist, he had brought Cambridge fame through his discovery of vitamins as accessory food substances needed in minute quantities, for which he was awarded the Nobel Prize in 1929. But his engaging, friendly and benign personality meant that ‘Hoppy’ headed an open and enquiring department, where no subject, including politics, was off-limits. He was popular and approachable with the advanced Part II students. He had appointed talented and sometimes controversial scientists, such as J. B. S. Haldane, Joseph Needham, Malcolm Dixon, Bill Pirie, Ernest Baldwin and Robin Hill. Among his appointments were the women scientists Dorothy Moyle (later Needham) and Marjorie Stephenson who became eminent in their fields. Hans Krebs and Ernst Chain – fleeing persecution from Nazi Germany and both to become future Nobel prize winners – were made welcome by Hopkins in the 1930s. In fact the department was affectionately known by some as the ‘Hopkins Matrimonial Agency’ because of the number of marriages between research workers and ‘Little Moscow’ because of the left-wing tendency of the Needhams, Pirie and others.
Fred described 1955–64 as his ‘lean years’ as he published relatively little then. In fact, this was a transitional period in which Fred was exploring completely new ideas for sequencing proteins. His idea was to radioactively label proteins. After radioactively labelling a protein and then isolating a radioactive peptide, he would work out the sequence around the labelled amino acid, indirectly. For example, he would use various modifications of the peptide, e.g. removal of the N-terminal amino acid, and monitor changes in the mobility of the peptide on paper chromatography or paper electrophoresis. He was using the position of the peptide as a way of sequencing.
This new way of thinking would, in principle, have many advantages. It would not require as much protein as his classical procedures worked out on insulin, since radioactively labelled peptides would be easily and quickly detected on paper by the then relatively new and sensitive method of autoradiography – using an X-ray film. The protein would not necessarily have to be pure, as long as it was radiochemically pure. For example in 1958 Fred incubated an isolated oviduct from a hen with 1 mCi 32P-labelled inorganic phosphate. He successfully isolated 32P-labelled ovalbumin, which was known then to contain two serine phosphates. Fred correctly deduced the presence of one phosphate-containing dipeptide, as serine phosphate-alanine, an observation confirmed ten years later by classical methods of peptide sequencing. Twenty years later on in 1978, in a very different era of DNA sequencing, my colleagues and I showed the exact position of this dipeptide in ovalbumin, as deduced from the nucleotide sequence of a cDNA clone of ovalbumin mRNA.
Fred Sanger (FS) and I (GB) are seated in a recording studio at Imperial College, London. This is a slightly edited transcript of the final interview.
Move to the new lab
GB At this time, in 1962, you moved to a new lab in Cambridge.
FS Yes, that’s right. This was to the Laboratory of Molecular Biology (Figure 44).
There were two groups in Cambridge, really, my own group working in Biochemistry and we had nothing to do with the teaching, so we were the poor relations. We were supported by the Medical Research Council (MRC). Then there was Perutz’s group in the Cavendish – working in the hut in front of the Cavendish. Both of us were looking for possibilities of new labs and expansion – particularly them. The MRC decided to build a new lab for us – the new Laboratory of Molecular Biology which was completed in 1961.
GB You took with you your own extended group.
FSYes, the new laboratory had three groups at that time. There was the Structural Studies group headed by Perutz, who was also head of the lab. John Kendrew, Aaron Klug and Hugh Huxley were there. And there was Francis Crick’s group, called Molecular Genetics, later Cell Biology. Sydney Brenner was in that group (Figure 45). There was my group (Figure 46) on the top floor, called Protein Chemistry. No mention of nucleic acids at that time. I was joined by various people, who had worked with me in Biochemistry – Leslie Smith who had been on the insulin work (Figure 41), Ieuan Harris (Figure 46) and Brian Hartley (Figure 46). Brian had worked on the important project of sequencing chymotrypsin. He completed that in the Molecular Biology Lab.
Fred Sanger (FS) and I (GB) are seated in a recording studio at Imperial College, London. This is a slightly edited transcript of the continuing interview.
Postgraduate research at Cambridge, 1940–1943
GBI’ve read, Fred, that at this stage you had still not quite decided to go into research.
FSWell, the thing is, I had not really decided that I was that good. I hadn’t been getting first classes in my Part I exams, and so I really didn’t have the confidence that I could do research. Usually you had to get a first to go into research. In this Part II Biochemistry there were all these brainy people who had got firsts in their Part I. They all seemed very clever compared to me. So at the end of the year I took the exams and I sort of went off and didn’t think too much about what I was going to do. In fact, I was thinking I would probably do some war work of some sort. War had broken out. But then, to my surprise, someone had seen in the paper that I had got a first. Actually, I was staying with my cousin. He was in the Air Force and he had been to the mess and he had just had a look at the Cambridge results in The Times and he’d seen I had got a first. And I said that’s ridiculous, it couldn’t be, but it was so. I had got a first. There were just two of us who had got firsts in this exam. So that changed my mind. So there was the possibility of doing research.
GBBut before you actually started research you had actually preplanned some training in Devon, I understand.
FSYes, that’s right, I went to a place called Spison (now Spiceland), a Quaker Relief Training Centre, which was a training place for conscientious objectors, where I was learning various things they could do to help save lives, instead of taking lives. We learned agriculture and a bit about building, and after I had done that course I went to work in a hospital, cleaning the floors and that sort of thing – just as an orderly. I started work there. That was the first job I had. I got 10 shillings (50p) a week for that.
Fred Sanger asked me to interview him for the Biochemical Society archives in October 1992. He never told me why he chose me as an interviewer rather than one of his many colleagues and friends in Cambridge. I had worked with Fred in Cambridge from 1963 to 1980 but by 1992 had moved to the Sir William Dunn School of Pathology at the University of Oxford. Naturally I was honoured and accepted. In that interview Fred Sanger gave a full and frank account of his life and provided some insight into what qualities he thought were needed to be a successful scientist. This biography is, in part, based on that interview.
Fred had an unusual upbringing and it may surprise many readers to learn that he was not initially committed to research. As a young man he had a strict Quaker upbringing. He was ambivalent about studying medicine, changing his mind to study biochemistry rather than medical subjects at Cambridge because his father, a doctor in general practice, was always rushing around attending to patients and ‘could not really concentrate on anything’. Both his parents died when he was an undergraduate, leaving him vulnerable. He doubted he was good enough to do research and applied at the last minute to study for a higher degree, a PhD, in biochemistry at Cambridge only after he learnt he had been awarded, to his surprise, a first class degree. Sanger was a conscientious objector in the Second World War. He learned to do research rather than killing the enemy.
In spite of this uncertain beginning to his career, he quickly showed aptitude for research. He seemed to have the ability to succeed in solving ‘impossible research problems’ where others had feared to tread. He was a ‘hands-on’ researcher doing research himself with the help of a trusted technical assistant right up to the end of his career. Many of his critical research findings were the result of his own findings carried out personally. This did not mean he was not a good leader. In fact he was a consummate team leader and early on attracted others to his research team because of his achievements and the great personal effort he made. This personal commitment to research inspired confidence in his many collaborators, including me. He was also unusual in stressing the contribution of the whole of his research team.